Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice

Clinical and Experimental Immunology

Volumn 168, Issue 3, 2012, Pages 268-273

  Nagayama, Y ^a   Nakahara, M ^a   Shimamura, M ^a   Horie, I ^a   Arima, K ^a   Abiru, N ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Graves' hyperthyroidism; Hashimoto's thyroiditis; Immunoproteasome; NOD H2 h4 mouse

Indexed keywords

AUTOANTIBODY; EPITOPE; IMMUNOMODULATING AGENT; IMMUNOPROTEASOME; IMMUNOPROTEASOME INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONYX 0914; PR 957; PROTEASOME; THYROGLOBULIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TREATMENT OUTCOME;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; IMMUNITY, CELLULAR; IODINE; MICE; MICE, INBRED NOD; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; TH1 CELLS; TH17 CELLS; THYROGLOBULIN; THYROID GLAND;

EID: 84859959246     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04578.x     Document Type: Article

References (25)

1. Braverman LE. Wermer and Ingbar's The thyroid. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000.
2. Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol Rev 1998; 163:161-76.
3. Groettrup M, Kirk CJ, Basler M. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 2010; 10:73-8.
4. Fehling HJ, Swat W, Laplace C etal. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994; 265:1234-7.
5. Van Kaer L, Ashton-Rickardt PG, Eichelberger M etal. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994; 1:533-41.
6. Basler M, Moebius J, Elenich L, Groettrup M, Monaco JJ. An altered T cell repertoire in MECL-1-deficient mice. J Immunol 2006; 176:6665-72.
7. Conner EM, Brand S, Davis JM etal. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997; 282:1615-22.
8. Fissolo N, Kraus M, Reich M etal. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008; 38:2401-11.
9. Lee SW, Kim JH, Park YB, Lee SK. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009; 68:1761-7.
10. Neubert K, Meister S, Moser K etal. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-55.
11. Inoue S, Nakase H, Matsuura M etal. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 2009; 156:172-82.
12. Muchamuel T, Basler M, Aujay MA etal. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15:781-7.
13. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010; 185:634-41.
14. Horie I, Abiru N, Nagayama Y etal. T helper type 17 immune response plays an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese diabetic-H2h4 mice. Endocrinology 2009; 150:5135-42.
15. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003; 111:1897-904.
16. Nagayama Y, Kita-Furuyama M, Ando T etal. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002; 168:2789-94.
17. Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+CD122+ T cells, a newly identified regulatory T subset, negatively regulate Graves' hyperthyroidism in a murine model. Endocrinology 2007; 148:6040-6.
18. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003; 170:3522-7.
19. Horie I, Abiru N, Sakamoto H, Iwakura Y, Nagayama Y. Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-{gamma} receptor, knockout nonobese diabetic-H2h4 mice. Endocrinology 2011; 152:4448-54.
20. Yu S, Sharp GC, Braley-Mullen H. Dual roles for IFN-gamma, but not for IL-4, in spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Immunol 2002; 169:3999-4007.
21. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocr Rev 2005; 26:800-32.
22. Nagayama Y, McLachlan SM, Rapoport B, Oishi K. Graves' hyperthyroidism and the hygiene hypothesis in a mouse model. Endocrinology 2004; 145:5075-9.
23. Hensley SE, Zanker D, Dolan BP etal. Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol 2010; 184:4115-22.
24. Arima K, Kinoshita A, Mishima H etal. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA 2011; 106:14914-19.
25. Agarwal AK, Xing C, DeMartino GN etal. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010; 87:866-72.